V
Verastem, Inc. (VSTM)
NCM – Real vaqt narxi. Valyuta: USD
4.63
-0.25 (-5.12%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
4.63
-0.25 (-5.12%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Verastem, Inc., rivojlanish bosqichidagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda saratonni davolash uchun dori vositalarini ishlab chiqish va tijoratlashtirishga qaratilgan. Uning mahsulot nomzodlari orasida Avutometinib mavjud bo'lib, u og'iz orqali qabul qilinadigan, kichik molekulali RAFF/MEK inhibitori bo'lib, MEK kinaza faoliyatini va yuqori RAFF tomonidan MEKning kompensatsion qayta faollashuvini bloklash uchun ishlab chiqilgan, shu bilan turli xil saratonlarda keng tarqalgan RAS/MAPK signalizatsiya yo'lini nishonga oladi; va Defatinib, turli xil qattiq o'smalar uchun FAK va prolin bilan boy tirozin kinazaning og'iz orqali qabul qilinadigan kichik molekulali inhibitori. Kompaniya klinik tadqiqotlarda ishtirok etadi, jumladan RAMP 301, takroriy darajasiz seroz tuxumdon saratoni bo'lgan bemorlarni davolash uchun Avutometinib va Defatinib kombinatsiyasini baholash uchun randomizatsiyalangan global tasdiqlovchi tadqiqot; RAMP 201, Avutometinibning samaradorligi va xavfsizligini baholash uchun moslashuvchan ikki qismli ko'p markazli, parallel kohortli, randomizatsiyalangan ochiq etiketli tadqiqot va Defatinib bilan birgalikda; FRAME, KRAS mutatsiyali saratonlarga chalingan bemorlarda Avutometinib va Defatinibni tadqiq qilish va keyingi tahlillar; va RAMP 205. Kompaniya Chugai Pharmaceutical Co., Ltd. bilan Avutometinibni o'z ichiga olgan mahsulotlarni ishlab chiqish, tijoratlashtirish va ishlab chiqarish bo'yicha litsenzion kelishuvlarga ega; va Pfizer Inc. bilan Pfizerning FAK inhibitorlarini insonlarda terapevtik, diagnostika va profilaktik maqsadlarda ishlatish uchun mahsulotlarni tadqiq qilish, ishlab chiqish, ishlab chiqarish va tijoratlashtirish bo'yicha kelishuvga ega. Bundan tashqari, u Amgen, Inc. bilan Avutometinibni Amgenning KRAS-G12C inhibitori LUMAKRAS bilan birgalikda baholash uchun klinik hamkorlik shartnomasiga ega, bu RAMP 203 deb nomlangan 1/2 bosqichli tadqiqotda amalga oshirilmoqda; VS-7375 va VS-7375-101 GenFleet Therapeutics bilan RAS yo'li orqali boshqariladigan saratonlarni nishonga oluvchi yangi dasturlarni ilgari surish bo'yicha kashfiyot va rivojlanish hamkorligidir; va AVMAPKI, FAKZYNJA, CO-PACK, bu avutometinib kapsulalari va defatinib tabletkalari. Kompaniya 2010 yilda tashkil etilgan va shtab-kvartirasi Needham, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jonathan Pachter Ph.D. | Chief Scientific Officer |
| Dr. Michael Glen Kauffman M.D., Ph.D. | President of Development & Director |
| Dr. Michelle Detwiler M.D., Ph.D. | Co-Founder |
| Dr. Robert A. Weinberg Ph.D. | Co-Founder & Chair of Scientific Advisory Board |
| Mr. Daniel Calkins | Chief Financial Officer |
| Mr. Daniel W. Paterson | President, CEO & Director |
| Mr. Mark J. Wanda | Senior VP of Legal & Chief Compliance Officer |
| Mr. Nathan Sanburn | Chief Business Officer |
| Ms. Cathy Carew | Chief Organizational Effectiveness Officer |
| Ms. Julissa Viana | Vice President of Corporate Communications & Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | tm2613842d1_8k.htm |
| 2026-04-09 | DEF 14A | vstm-20260521xdef14a.htm |
| 2026-03-04 | 8-K | tm267866d1_8k.htm |
| 2026-02-04 | 8-K | tm265057d1_8k.htm |
| 2026-01-08 | 8-K | tm262531d1_8k.htm |
| 2025-12-31 | 8-K | tm2534532d1_8k.htm |
| 2025-12-19 | 8-K | tm2533463d1_8k.htm |
| 2025-11-04 | S-8 | tm2530192d1_s8.htm |
| 2025-10-23 | 8-K | tm2529362d1_8k.htm |
| 2025-10-20 | 8-K | tm2529024d1_8k.htm |